The Dow Hangs Tough as Pfizer, Merck Offset Telecom Weakness

Pharma stocks are doing well on mixed news from the merger front.

May 19, 2014 at 11:00AM
Longview

On Monday morning, the Dow Jones Industrials (DJINDICES:^DJI) stayed within a narrow range, initially losing about 50 points but clawing back most of that loss within the first hour of the trading day. As of 11 a.m. EDT, the Dow was down just eight points. Although a few stragglers remain to report first-quarter earnings and economic data reports still have the power to move the Dow, most of investors' attention today went to the mergers and acquisitions arena, where pharma stocks did well even as telecoms lagged following the announcement of a big merger in that arena. Pfizer (NYSE:PFE) shareholders celebrated what appears to be the end of its buyout bid for AstraZeneca, while Merck (NYSE:MRK) climbed in the aftermath of its sale of its consumer-products division to Bayer.

Pfizer jumped 1.5% after the drug giant made what it called its final bid for its British counterpart, which was promptly rejected. Ordinarily, given shareholders' positive reception to the news of the original merger bid, you wouldn't expect Pfizer stock to climb after what appears to be the end of the drugmaker's efforts to boost growth, earn cost savings, and make a highly advantageous tax-home move across the Atlantic. But this morning's advance in the share price shows that Pfizer shareholders believe the bidding was getting too high, and investors are breathing a collective sigh of relief in the hopes that Pfizer will maintain its discipline and not try to pay an even higher price tag than the last $117 billion offer. Strategically, the rejections might be a setback for Pfizer, but the drug company still has solid long-term prospects and a healthy cash hoard to use for other acquisition ideas if it wants.

Mrk Vaccine

Source: Merck.

Meanwhile, Merck gained 0.6% as investors begin to look at the possibilities that will emerge from the sale of its consumer-care segment to Bayer. Most investors have focused on the $14 billion in cash that will change hands as a result of the deal, as well as the cost savings and profit boost that Merck could enjoy from divesting the division in order to focus more on its core pharmaceutical business. But in addition to the change of hands for consumer care, the agreement between Bayer and Merck also calls for collaboration on developing drug prospects in the cardiovascular space together. With Merck facing intense competition in other hot areas of the drug market, such as hepatitis C treatments, the possibility of improving its standing in the cardiovascular realm is attractive. Investors hope the company will succeed in getting cash and pipeline enhancement from the deal, and there's every reason to be optimistic that Merck could look much better in the near future as an investment prospect.

Invest in the next wave of health-care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers